Pharmacokinetic of Everolimus and Atorvastatin Co-administration
Status:
Completed
Trial end date:
2013-01-01
Target enrollment:
Participant gender:
Summary
Hypothesis : In renal transplantation recipient who received immunosuppressive drug
"certican" and have hypercholesterolemia will get lipid lower drug-HMG Co-A reductase
inhibitors. Because atorvastatin and everolimus have metabolism via Cytochrome P450 subfamily
3A4 both, so investigator made the hypothesis that when patients received everolimus with
atorvastatin will change area under the time concentration curve of everolimus.